Cardiff University

BioCentury’s roundup of translational innovations

U.K. company untangling genomic interactions to find targets in complex diseases

Bent Jakobsen’s newest biotech is replacing the virus’ natural tropisms with an integrin-based cancer targeting mechanism

CGT Catapult, UK DRI to work with academic centers to identify assets

Start-up’s MR1T cell therapy designed to address broader range of cancers than CAR T, TCR therapies

Aspen is navigating a path to the clinic through the COVID-19 crisis with its OrbiMed-led venture round

Immune system biomarkers take center stage among emerging targets at ASH 2019

Ervaxx is parlaying a new source of neoantigens into off-the-shelf cancer vaccines